BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Gene alterations in the PI3K and HR pathways are common in prostate cancer. Based on preclinical studies, the inhibition of PI3K disrupts HR, and PARP blockade induces AKT activation, supporting the combination of PI3Ki and PARPi. Herein, we investigated the safety and preliminary efficacy of the PI3Ki copanlisib and the PARPi rucaparib in patients with or without alterations in HR repair pathway genes.
Authors
- Matthew J. Hadfield (ORCID: https://orcid.org/0000-0001-5824-1286)
- Jeannine Margolis (ORCID: https://orcid.org/0009-0002-5747-4939)
- Sheldon L. Holder (ORCID: https://orcid.org/0000-0002-8959-2879)
- Adam J. Olszewski (ORCID: https://orcid.org/0000-0002-6472-6658)
- Anthony Mega (ORCID: https://orcid.org/0009-0008-6409-9325)
- Benedito A. Carneiro (ORCID: https://orcid.org/0000-0002-5468-1126)
- Wafik S. El‐Deiry (ORCID: https://orcid.org/0000-0002-9577-8266)
- Roxanne Wood (ORCID: https://orcid.org/0009-0007-3623-4959)
- Rahul Aggarwal (ORCID: https://orcid.org/0000-0001-7003-7982)
- Shaolei Lu (ORCID: https://orcid.org/0000-0003-2870-5793)
- André Souza (ORCID: https://orcid.org/0009-0008-1831-1719)
- Kate Anderson (ORCID: https://orcid.org/0009-0007-1561-7766)
- Dragan J. Golijanin (ORCID: https://orcid.org/0009-0004-4477-2173)
Institutions
- John Brown University (US)
- University of California, San Francisco (US)
- Brown University (US)
- New England Institute of Technology (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0651
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bayer
- Brown University
- Clovis Oncology